Skip to main content
SpringerLink
Log in

Immune-Mediated Liver Disease in the Transplanted Liver

  • Chapter
  • First Online:
Liver Immunology

  • 2427 Accesses

Abstract

Liver transplantation has evolved as the treatment of choice for many patients with end-stage liver disease (Fig. 30.1). Currently, survival post-transplant is excellent, with 1-, 3- and 5-year survival of 87 %, 78 % and 73 %, respectively [1]. Patients are selected for listing when estimated survival without transplantation is less than with transplantation; organs from deceased donors are allocated primarily on a needs-based system with the MELD (Model for End-Stage Liver Disease) score being the most widely used scoring system (Table 30.1) [2]. Transplant benefit develops when the MELD score reaches 15.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. 2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999–2008.

    Google Scholar 

  2. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.

    Article  PubMed  Google Scholar 

  3. McCormack L, Dutkowski P, El-Badry AM, Clavien PA. Liver transplantation using fatty livers: always feasible? J Hepatol. 2011;54(5):1055–62.

    Article  PubMed  Google Scholar 

  4. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. J Gastroenterol Hepatol. 2011;26 Suppl 1:173–9.

    Article  PubMed  CAS  Google Scholar 

  5. Zhai Y, Busuttil RW, Kupiec-Weglinski JW. Liver ischemia and reperfusion injury: new insights into mechanisms of innate-adaptive immune-mediated tissue inflammation. Am J Transplant. 2011;11(8):1563–9.

    Article  PubMed  CAS  Google Scholar 

  6. Abu-Amara M, Yang SY, Tapuria N, Fuller B, Davidson B, Seifalian A. Liver ischemia/reperfusion injury: processes in inflammatory networks—a review. Liver Transpl. 2010;16(9):1016–32.

    Article  PubMed  Google Scholar 

  7. Dhillon N, Walsh L, Krüger B, Ward SC, Godbold JH, Radwan M, et al. A single nucleotide polymorphism of Toll-like receptor 4 identifies the risk of developing graft failure after liver transplantation. J Hepatol. 2010;53(1):67–72.

    Article  PubMed  CAS  Google Scholar 

  8. Klaassen CD, Reisman SA. Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. Toxicol Appl Pharmacol. 2010;244(1):57–65.

    Article  PubMed  CAS  Google Scholar 

  9. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89–116.

    Article  PubMed  CAS  Google Scholar 

  10. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol. 2011;85(4):241–72.

    Article  PubMed  CAS  Google Scholar 

  11. Jaeschke H, Woolbright BL. Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species. Transplant Rev (Orlando). 2012;26(2):103–14.

    Article  Google Scholar 

  12. Jegatheeswaran S, Siriwardena AK. Experimental and clinical evidence for modification of hepatic ischaemia-reperfusion injury by N-acetylcysteine during major liver surgery. HPB (Oxford). 2011;13(2):71–8.

    Article  Google Scholar 

  13. Tsuchihashi S, Fondevila C, Kupiec-Weglinski JW. Heme oxygenase system in ischemia and reperfusion injury. Ann Transplant. 2004;9(1):84–7.

    PubMed  CAS  Google Scholar 

  14. Jassem W, Fuggle SV, Cerundolo L, Heaton ND, Rela M. Ischemic preconditioning of cadaver donor livers protects allografts following transplantation. Transplantation. 2006;81(2):169–74.

    Article  PubMed  Google Scholar 

  15. Dal Ponte C, Alchera E, Follenzi A, Imarisio C, Prat M, Albano E, et al. Pharmacological postconditioning protects against hepatic ischemia/reperfusion injury. Liver Transpl. 2011;17(4):474–82.

    Article  PubMed  Google Scholar 

  16. Li F, Atz ME, Reed EF. Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways. Curr Opin Immunol. 2009;21(5):557–62.

    Article  PubMed  CAS  Google Scholar 

  17. Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant. 2008;13(4):438–44.

    Article  PubMed  Google Scholar 

  18. Kroemer A, Edtinger K, Li XC. The innate natural killer cells in transplant rejection and tolerance induction. Curr Opin Organ Transplant. 2008;13(4):339–43.

    Article  PubMed  Google Scholar 

  19. Klein I, Crispe IN. Complete differentiation of CD8+ T cells activated locally within the transplanted liver. J Exp Med. 2006;203(2):437–47.

    Article  PubMed  Google Scholar 

  20. Kern M, Popov A, Kurts C, Schultze JL, Knolle PA. Taking off the brakes: T cell immunity in the liver. Trends Immunol. 2010;31(8):311–7.

    Article  PubMed  CAS  Google Scholar 

  21. Crispe IN. Hepatic T, cells and liver tolerance. Nat Rev Immunol. 2003;3(1):51–62.

    Article  PubMed  CAS  Google Scholar 

  22. McDonald B, McAvoy EF, Lam F, Gill V, de la Motte C, Savani RC, et al. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. J Exp Med. 2008;205(4):915–27.

    Article  PubMed  CAS  Google Scholar 

  23. Shetty S, Weston CJ, Oo YH, Westerlund N, Stamataki Z, Youster J, et al. Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J Immunol. 2011;186(7):4147–55.

    Article  PubMed  CAS  Google Scholar 

  24. Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams DH. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol. 2002;169(2):983–92.

    PubMed  CAS  Google Scholar 

  25. Goddard S, Williams A, Morland C, Qin S, Gladue R, Hubscher SG, et al. Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation. 2001;72(12):1957–67.

    Article  PubMed  CAS  Google Scholar 

  26. Hübscher SG. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant. 2012;17(3):280–6.

    PubMed  Google Scholar 

  27. Hübscher SG, Adams DH, Buckels JA, McMaster P, Neuberger J, Elias E. Massive haemorrhagic necrosis of the liver after liver transplantation. J Clin Pathol. 1989;42(4):360–70.

    Article  PubMed  Google Scholar 

  28. O’Grady JG, Hardy P, Burroughs AK, Elbourne D. UK and Ireland Liver Transplant Study Group. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant. 2007;7(1):137–41.

    Article  PubMed  Google Scholar 

  29. Warlé MC, Metselaar HJ, Hop WC, Tilanus HW. Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transpl. 2005;11(1):19–26.

    Article  PubMed  Google Scholar 

  30. de Reuver P, Pravica V, Hop W, Boor P, Metselaar HJ, Hutchinson IV, et al. Recipient ctla-4 +49 G/G genotype is associated with reduced incidence of acute rejection after liver transplantation. Am J Transplant. 2003;3(12):1587–94.

    Article  PubMed  Google Scholar 

  31. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation. 2005;80(5):555–63.

    Article  PubMed  Google Scholar 

  32. Kitchens WH, Uehara S, Chase CM, Colvin RB, Russell PS, Madsen JC. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation. 2006;81(6):811–7.

    Article  PubMed  Google Scholar 

  33. Hanvesakul R, Spencer N, Cook M, Gunson B, Hathaway M, Brown R, et al. Donor HLA-C genotype has a profound impact on the clinical outcome following liver transplantation. Am J Transplant. 2008;8(9):1931–41.

    Article  PubMed  CAS  Google Scholar 

  34. Rodríguez-Perálvarez M, Germani G, Tsochatzis E, Rolando N, Luong TV, Dhillon AP, et al. Predicting severity and clinical course of acute rejection after liver transplantation using blood eosinophil count. Transpl Int. 2012;25(5):555–63.

    Article  PubMed  Google Scholar 

  35. Bolognesi M, Sacerdoti D, Mescoli C, Nava V, Bombonato G, Merkel C, et al. Acute liver rejection: accuracy and predictive values of Doppler US measurements—initial experience. Radiology. 2005;235(2):651–8.

    Article  PubMed  Google Scholar 

  36. Hübscher SG. What is the long-term outcome of the liver allograft? J Hepatol. 2011;55(3):702–17.

    Article  PubMed  Google Scholar 

  37. Shaked A, Ghobrial RM, Merion RM, Shearon TH, Emond JC, Fair JH, et al. A2ALL Study Group. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am J Transplant. 2009;9(2):301–8.

    Article  PubMed  CAS  Google Scholar 

  38. Calne RY. WOFIE hypothesis: some thoughts on an approach toward allograft tolerance. Transplant Proc. 1996;28:1152.

    PubMed  CAS  Google Scholar 

  39. Höroldt BS, Burattin M, Gunson BK, Bramhall SR, Nightingale P, Hübscher SG, et al. Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation? Liver Transpl. 2006;12(7):1144–51.

    Article  PubMed  Google Scholar 

  40. Neil DA, Hübscher SG. Current views on rejection pathology in liver transplantation. Transpl Int. 2010;23(10):971–83.

    Article  PubMed  Google Scholar 

  41. Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology. 2000;31(3):792–9.

    Article  PubMed  CAS  Google Scholar 

  42. Nishida S, Pinna A, Verzaro R, Levi D, Kato T, Khan F, et al. Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation. Transplant Proc. 2001;33(1–2):1495.

    Article  PubMed  CAS  Google Scholar 

  43. Pfitzmann R, Klupp J, Langrehr JM, Uhl M, Neuhaus R, Settmacher U, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation. 2003;76(1):130–6.

    Article  PubMed  CAS  Google Scholar 

  44. Shaikh OS, Demetris AJ. Idiopathic posttransplantation hepatitis? Liver Transpl. 2007;13(7):943–6.

    Article  PubMed  Google Scholar 

  45. Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Uemoto S, Manabe T. Idiopathic post-transplantation hepatitis following living donor liver transplantation, and significance of autoantibody titre for outcome. Transpl Int. 2009;22(3):303–12.

    Article  PubMed  CAS  Google Scholar 

  46. Pischke S, Suneetha P, Baechlein C, Barg-Hock H, Heim A, Kamar N, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl. 2009;16(1):74–82.

    Article  Google Scholar 

  47. Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology. 2006;43(5):1109–17.

    Article  PubMed  Google Scholar 

  48. Seyam M, Neuberger JM, Gunson BK, Hubscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl. 2007;13(7):966–74.

    Article  PubMed  Google Scholar 

  49. Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol. 2010;10(11):753–66.

    Article  PubMed  CAS  Google Scholar 

  50. Jukes JP, Jones ND. Immunology in the Clinic Review Series; focus on host responses: invariant natural killer T cell activation following transplantation. Clin Exp Immunol. 2012;167(1):32–9.

    Article  PubMed  CAS  Google Scholar 

  51. Sánchez-Fueyo A. Hot-topic debate on tolerance: immunosuppression withdrawal. Liver Transpl. 2011;17 Suppl 3:S69–73.

    Article  PubMed  Google Scholar 

  52. Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 1998;351:1701–2.

    Article  PubMed  CAS  Google Scholar 

  53. Londoño MC, Rimola A, O’Grady J, Sanchez-Fueyo A. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol. 2013;59(4):872–9. doi: 10.1016/j.jhep.2013.04.003. Epub 2013 Apr 8.

    Google Scholar 

  54. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010;120(6):1836–47.

    Article  PubMed  CAS  Google Scholar 

  55. Bohne F, Martinez-Llordella M, Lozano JJ, Miquel R, Benítez C, Londoño MC, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest. 2012;122(1):368–82.

    Article  PubMed  CAS  Google Scholar 

  56. Farid WR, Pan Q, van der Meer AJ, Ramakrishnaiah V, de Jonge J, Kwekkeboom J, et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl. 2012;18(3):290–7.

    Article  PubMed  Google Scholar 

  57. Marín LA, Moya-Quiles MR, Miras M, Minguela A, Bermejo J, Ramírez P, et al. Evolution of soluble forms of CD86, CD95 and CD95L molecules in liver transplant recipients. Transpl Immunol. 2012;26(2–3):94–100.

    Article  PubMed  Google Scholar 

  58. Adam R, McMaster P, O’Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl. 2003;9:1231–43.

    Article  PubMed  Google Scholar 

  59. Kashyap R, Safadjou S, Chen R, Mantry P, Sharma R, Patil V, et al. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases—an analysis of the UNOS database. J Gastrointest Surg. 2010;14:1362–9.

    Article  PubMed  Google Scholar 

  60. Yoshida EM, Singh RA, Vartanian RK, Owen DA, Erb SR, Scudamore CH. Late recurrent post-transplant primary biliary cirrhosis in British Columbia. Can J Gastroenterol. 1997;11:229–33.

    PubMed  CAS  Google Scholar 

  61. Hashimoto E, Shimada M, Noguchi S, Taniai M, Tokushige K, Hayashi N, et al. Disease recurrence after living liver transplantation for primary biliary cirrhosis: a clinical and histological follow-up study. Liver Transpl. 2001;7:588–95.

    Article  PubMed  CAS  Google Scholar 

  62. Klein R, Huizenga JR, Gips CH, Berg PA. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis before orthotopic liver transplantation and titres of antimitochondrial antibody-subtypes after transplantation. J Hepatol. 1994;20:181–9.

    Article  PubMed  CAS  Google Scholar 

  63. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2004;10:488–91.

    Article  PubMed  Google Scholar 

  64. Mason AL. The evidence supports a viral aetiology for primary biliary cirrhosis. J Hepatol. 2011;54(6):1312–4.

    Article  PubMed  Google Scholar 

  65. Manousou P, Arvaniti V, Tsochatzis E, Isgro G, Jones K, Shirling G, et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl. 2010;16(1):64–73.

    Article  PubMed  Google Scholar 

  66. Morioka D, Egawa H, Kasahara M, Jo T, Sakamoto S, Ogura Y, et al. Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver Transpl. 2007;13(1):80–90.

    Article  PubMed  Google Scholar 

  67. Blan V, Ruppert K, Demetris AJ, Ledneva T, Duquesnoy RJ, Detre KM, et al. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Hepatology. 2008;48(3):878–88.

    Article  Google Scholar 

  68. Robertson H, Kirby JA, Yip WW, Jones DE, Burt AD. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology. 2007;45(4):977–81.

    Article  PubMed  CAS  Google Scholar 

  69. Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, et al. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology. 2011;53(5):1685–95.

    Article  PubMed  Google Scholar 

  70. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2007;13:1236–45.

    Article  PubMed  Google Scholar 

  71. Jacob DA, Neumann UP, Bahra M, Klupp J, Puhl G, Neuhaus R, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant. 2006;20:211–20.

    Article  PubMed  Google Scholar 

  72. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int. 2008;21(5):459–65.

    Article  PubMed  Google Scholar 

  73. Tischendorf JJ, Hecker H, Krüger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102(1):107–14.

    Article  PubMed  Google Scholar 

  74. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12:1813–24.

    Article  PubMed  Google Scholar 

  75. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, La Russo NF, Porayko MK, et al. Recurrence of primary sclerosing cholangitis after liver transplantation. Hepatology. 1999;29:1050–6.

    Article  PubMed  CAS  Google Scholar 

  76. Jeyarajah DR, Netto GJ, Lee SP, Testa G, Abbasoglu O, Husberg BS, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation. 1998;27:1300–6.

    Article  Google Scholar 

  77. Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2002;8:575–81.

    Article  PubMed  Google Scholar 

  78. Graziadei IW. Live donor liver transplantation for primary sclerosing cholangitis: is disease recurrence increased? Curr Opin Gastroenterol. 2011;27(3):301–5.

    Article  PubMed  Google Scholar 

  79. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15(3):330–40.

    Article  PubMed  Google Scholar 

  80. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6(3):244–51.

    Article  PubMed  CAS  Google Scholar 

  81. Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: A comprehensive review. J Autoimmunity. 2013.

    Google Scholar 

  82. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 2008;14(2):181–5.

    Article  PubMed  Google Scholar 

  83. Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol. 2004;99(3):538–42.

    Article  PubMed  Google Scholar 

  84. Gelson W, Hoare M, Dawwas MF, Vowler S, Gibbs P, Alexander G. The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation. 2011;91(11):1240–4.

    Article  PubMed  Google Scholar 

  85. Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis. 2009;29(3):286–96.

    Article  PubMed  Google Scholar 

  86. Ilyas JA, O’Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol. 2011;25(6):765–82.

    Article  PubMed  Google Scholar 

  87. Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl. 2001;7:285–91.

    Article  PubMed  CAS  Google Scholar 

  88. Liberal R, Longhi MS, Mieli-Vergani G, Vergani D. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol. 2011;25(6):653–64.

    Article  PubMed  CAS  Google Scholar 

  89. Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology. 2000;32:185–92.

    Article  PubMed  CAS  Google Scholar 

  90. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun. 2010;34(1):7–14.

    Article  PubMed  CAS  Google Scholar 

  91. Montano-Loza AJ, Vargas-Vorackova F, Ma M, Bain VG, Burak K, Kumar T, et al. Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation. Liver Int. 2012;32:1426–33.

    Article  PubMed  Google Scholar 

  92. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol. 2004;40:3–7.

    Article  PubMed  Google Scholar 

  93. Fiel MI, Agarwal K, Stanca C, Elhaji N, Kontorinis N, Thung S, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with HCV. Liver Transpl. 2008;14:861–71.

    Article  PubMed  Google Scholar 

  94. Khettry U, Huang WY, Simpson MA, Pomfret EA, Pomposelli JJ, Lewis WD, et al. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol. 2007;38:443–52.

    Article  PubMed  Google Scholar 

  95. Aguilera J, Sousa JM, Gavilán F, Bernardos A, Wichmann I, Nuñez-Roldán A. Glutathione-S-transferase T1 mismatch constitutes a risk factor for de novo autoimmune hepatitis after liver transplantation. Liver Transpl. 2004;10:1166–72.

    Article  PubMed  Google Scholar 

  96. Venick RS, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant. 2007;7:955–63.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Centre for Liver Research and NIHR Biomedical Research Unit, University of Birmingham, Birmingham, UK

      Palak Jitendrakumar Trivedi M.B.B.S., M.Sc., M.R.C.P., Ka-Kit Li M.B.Ch.B, M.R.C.P. & James Neuberger

    2. Liver Unit, Queen Elizabeth Hospital, Birmingham, UK

      Palak Jitendrakumar Trivedi M.B.B.S., M.Sc., M.R.C.P., Ka-Kit Li M.B.Ch.B, M.R.C.P. & James Neuberger

    3. National Health Service Blood and Transplant, Bristol, UK

      James Neuberger

    Authors
    1. Palak Jitendrakumar Trivedi M.B.B.S., M.Sc., M.R.C.P.
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Ka-Kit Li M.B.Ch.B, M.R.C.P.
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. James Neuberger
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Palak Jitendrakumar Trivedi M.B.B.S., M.Sc., M.R.C.P. .

    Editor information

    Editors and Affiliations

    1. Division of Rheumatology, Allergy and Clinical Immunology, University of California School of Medicine, Davis, California, USA

      M. Eric Gershwin

    2. Medicine and Surgery, Baylor College of Medicine, Houston, Texas, USA

      John M. Vierling

    3. Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Germany

      Michael P. Manns

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2014 Springer Science+Business Media New York

    About this chapter

    Cite this chapter

    Trivedi, P.J., Li, KK., Neuberger, J. (2014). Immune-Mediated Liver Disease in the Transplanted Liver. In: Gershwin, M., Vierling, J., Manns, M. (eds) Liver Immunology. Springer, Cham. https://doi.org/10.1007/978-3-319-02096-9_30

    Download citation

    • DOI: https://doi.org/10.1007/978-3-319-02096-9_30

    • Published:

    • Publisher Name: Springer, Cham

    • Print ISBN: 978-3-319-02095-2

    • Online ISBN: 978-3-319-02096-9

    • eBook Packages: MedicineMedicine (R0)

    Publish with us

    Policies and ethics

    Search

    Navigation